Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies.

导出 LinkOut

翻译打印收藏纠错

第一作者： Ruth,Maron

第一单位： Department of Immunology, Weizmann Institute of Science, Rehovot, 76100, Israel.

作者： Ruth,Maron ^[1] ; Bilha,Schechter ^[1] ; Nishanth Belugali,Nataraj ^[2] ; Soma,Ghosh ^[2] ; Donatella,Romaniello ^[2] ; Ilaria,Marrocco ^[2] ; Ashish,Noronha ^[2] ; Silvia,Carvalho ^[3] ; Yosef,Yarden ^[4] ; Michael,Sela ^[5]

作者单位： Department of Immunology, Weizmann Institute of Science, Rehovot, 76100, Israel. ^[1] Department of Biological Regulation, Weizmann Institute of Science, Rehovot, 76100, Israel. ^[2] Israel National Center for Personalized Medicine (INCPM), Weizmann Institute of Science, Rehovot, 76100, Israel. ^[3] Department of Biological Regulation, Weizmann Institute of Science, Rehovot, 76100, Israel. Electronic address: yosef.yarden@weizmann.ac.il. ^[4] Department of Immunology, Weizmann Institute of Science, Rehovot, 76100, Israel. Electronic address: michael.sela@weizmann.ac.il. ^[5]

关键词 EGFR/ERBB1 HER2/ERBB2 Homo-combination Monoclonal antibody Pancreatic cancer

主题词动物(Animals);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);疾病模型, 动物(Disease Models, Animal);女(雌)性(Female);小鼠, 裸(Mice, Nude);胰腺肿瘤(Pancreatic Neoplasms)

DOI 10.1016/j.bbrc.2019.03.204

PMID 30952434

发布时间 2020-04-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交